Cargando…
MEDB-43. Development of a bioinformatics pipeline for identification of differential DNA methylation events associated with medulloblastoma relapse
Relapsed medulloblastoma (rMB) is treatment-resistant and fatal in ~95% of cases. The epigenetic features of rMB, and any role as drivers of disease relapse/treatment-resistance have yet to be investigated. We therefore developed a pipeline to identify differentially methylated CpGs (DM-CpGs) and re...
Autores principales: | Kui, Christopher, Richardson, Stacey, Schwalbe, Edward C, Thompson, Dean, Keeling, Claire, Strathdee, Gordon, Dufour, Christelle, Bailey, Simon, Ramaswamy, Vijay, Clifford, Steven C, Hill, Rebecca M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164906/ http://dx.doi.org/10.1093/neuonc/noac079.417 |
Ejemplares similares
-
MEDB-31. THE CLINICAL SIGNIFICANCE OF EXTENT OF RESECTION IN MEDULLOBLASTOMA
por: Keeling, Claire, et al.
Publicado: (2022) -
MEDB-71. Molecular characterisation of group 4 medulloblastoma improves risk-stratification and its biological understanding
por: Goddard, Jack, et al.
Publicado: (2022) -
MEDB-36. Clinical and molecular heterogeneity withinMYC andMYCN amplified medulloblastoma
por: Schwalbe, Edward, et al.
Publicado: (2022) -
MEDB-49. Relapsed SHH medulloblastomas in young children. Are there alternatives to full-dose craniospinal irradiation?
por: Erker, Craig, et al.
Publicado: (2022) -
MEDB-21. SOX2(+) cells: the perpetrators of medulloblastoma relapse
por: Swiderska-Syn, Marzena, et al.
Publicado: (2022)